Baseline Productions

Baseline Productions LT Debt/Equity

Long-Term Debt to Equity Ratio of Baseline Productions (BSSP) as of Nov 15, 2026.

LT Debt/Equity

0.00

Last updated:

Long-Term Debt to Equity Ratio of Baseline Productions is 2020 0.00 . Long-Term Debt to Equity Ratio of Baseline Productions was 2019 0.00 . It decreases by % lower compared to the previous year.

The Baseline Productions LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2014
-0.23 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
The Baseline Productions LT Debt/Equity history
YEARLT Debt/EquityYoY
0.00—
0.00-100.00%
-0.23—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Baseline Productions Stock analysis

What does Baseline Productions do? Baseline Productions Inc develops mobile based hardware and software based products. The company focuses on commercialization of its proteins for cancer and infectious disease treatments. Its Irreversible Pepsin Fraction (IPF) technology activates the immune system to fight autoimmune diseases. IPF binds to T-cells and triggers Th1 responses that eliminate infected cells. The firm's lead compound is an IPF suspension for autoimmune disease treatment including cancer, cirrhosis, and Hepatitis C. The product IMMUNE-THERAPEUTIC PROTEIN (ITP) is a therapeutic protein derived from porcine pepsin, which is irreversible, modified, and fractionated to IPF sequence. The company sells its IPF platform technology and ITP product to healthcare providers and pharmaceutical companies. Healthcare providers use IPF for immune system activation in autoimmune disease treatment. Pharmaceutical companies purchase ITP for development into therapeutic applications. The target segments include medical institutions treating autoimmune conditions and drug manufacturers seeking novel protein-based therapies. ITP is specifically indicated for cancer, cirrhosis, and Hepatitis C treatment. Baseline Productions generates revenue through licensing IPF technology and selling ITP therapeutic protein. The IPF platform is sold as a technology solution to partners in the healthcare sector. ITP is marketed as a therapeutic product for direct sale to medical facilities. The company's primary customers are healthcare institutions and pharmaceutical firms interested in immune system-based treatments for autoimmune diseases and infectious conditions. Baseline Productions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Baseline Productions stock

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Baseline Productions since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Baseline Productions with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Baseline Productions

All Key Metrics — Baseline Productions